the biomarkers of lupus disease study a bold approach may mitigate interference of background immunosuppressants in clinical trials.arthritis r文档.pdf

Full Length Arthritis Rheumatology DOI 10.1002/art.40086 Running head: Biomarkers of Lupus Disease (BOLD) The Biomarkers of Lupus Disease Study: a Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials Authors: 1* 3 Joan T Merrill, MD , Fred Immermann, MStat , Maryann Whitley, PhD , Tianhui Zhou, PhD , 5 Andrew Hill, PhD , Margot OToole, PhD , Padmalatha Reddy, PhD , Marek Honczarenko, MD, 4 1 1 6 PhD , Aikaterini Thanou, MD , Joe Rawdon, DNP , Joel M Guthridge, PhD , Judith A James, MD, PhD6‡, Sudhakar Sridharan, MD7‡ Affiliations: 1 Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and Department of Medicine and School of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA Pfizer, Inc, Cambridge, MA USA 3 GlaxoSmith Kline, Boston, MA USA 4 Bristol Myers Squibb, Inc, Princeton, NJ USA 5 Independent Consultant, Boston, MA USA 6 Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and Departments of Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA 7 Pharmaceutical Product Development, Inc, Rockville, MD USA ‡ These authors contributed equally *To whom correspondence should be addressed: Joan T Merrill, MD Oklahoma Medical Rese